Table 4.

First-line therapy among stage IV NSCLC adenocarcinoma patients with a positive molecular test result

Type of therapy	Number of patients	%
Molecular test
Treatment administered
First-line targeted therapy
EGFR positive	558
Targeted treatment administereda	457	81.9
Afatinib	99	21.7
Erlotinib	65	14.2
Gefitinib	197	43.1
Osimertinib	94	20.6
Other	14	3.1
No drug administered	101	18.1
ALK gene rearrangement	46
Targeted treatment administeredb	30	65.2
Alectinib	21	70.0
Ceritinib	4	13.3
Crizotinib	5	16.7
Other	2	6.7
No drug administered	16	34.8
ROS1 gene rearrangement	13
Targeted treatment administered	4	30.8
Alectinib	0	0
Ceritinib	0	0
Crizotinib	4	100.0
Other	0	0
No drug administered	9	69.2

^a10 cases took two different drugs, one case took three different drugs.

^bTwo cases took two different drugs.